草酸铂联合希罗达治疗晚期结直肠癌的疗效研究  

Oxaliplatin Combined with Xeloda in the Treatment of Advanced Colorectal Cancer

作　　者：高宏丽[1] 张兆明[1] 崔海青[1] 张晓[1] 

机构地区：[1]山东省济南市第四人民医院内科,250031

出　　处：《中国全科医学》2007年第13期1072-1074,共3页Chinese General Practice

摘　　要：目的评价草酸铂联合希罗达方案治疗晚期结直肠癌的疗效与安全性。方法48例草酸铂联合希罗达治疗的晚期结直肠癌患者(XELOX组)与同时期收治的40例草酸铂联合5-氟尿嘧啶/亚叶酸钙治疗的晚期结直肠癌患者(OLF组)进行对比观察。结果XELOX组48例患者中完全缓解(CR)0例,总分缓解(PR)21例,稳定(SD)18例,进展(PD)9例;中位肿瘤进展时间(TTP)7.9个月。OLF组40例患者中CR0例,PR16例,SD14例,PD10例;中位TTP7.0个月。两组疗效间差异无显著性意义(P>0.05),两组均无严重的化疗相关不良反应,两组患者骨髓抑制、恶心和呕吐、腹泻、口腔炎、周围神经异常的发生率间差别无显著性意义(P>0.05),XELOX组较突出的不良反应为手足综合征,与OLF组比较差异有显著性意义(P<0.05)。结论草酸铂联合希罗达方案治疗晚期结直肠癌给药方便,疗效确切,耐受性较好。Objective To evaluate the efficacy and safety of combined chemotherapy with Oxaliplatin and Xeloda in advanced colorectal cancer. Methods Some 48 patients of advanced colorectal cancer were treated with oxaliplatin combined with xeloda （ XELOX group） , and were compared with another 40 patients of advanced colorectal cancer during the same period who were treated with oxaliplatin combined with fluorouracl/leucovorin （OLF group）. Results In the XELOX group of 48 cases among which there were 0 CR, 21PR, 18SD, and 9 PD, the overall effective rate was 43.8% , and the mTTP was 7.9 months. In the OLF group of 40 cases among which there were 0 CR, 16 PR, 14 SD, 10 PD, the effective rate was 40. 0% , and the m TTP was 7 months. The effectiveness of the two groups had no significant difference （ P 〉 0. 05 ） , and there was no serious chemotherapy related adverse effect in the two groups. The rates of marrow inhibition, nausea, vomit, diarrhea, mouth ulcer and peripheral neuritis were similar in both the groups. The main adverse effect in XELOX group was hand - foot syndrome, with a significant difference compared with OLF group. Conclusion The combined chemotherapy with oxaliplatin and xeloda is convenient to administer, with definite effectiveness and better- tolerated for treatment of advanced colorectal cancer.

关 键 词：直肠肿瘤 草酸铂 希罗达 5-氟尿嘧啶 抗肿瘤联合化疗方案 

分 类 号：R735.37[医药卫生—肿瘤]